Shopping Cart 0
Cart Subtotal
USD 0

Percutaneous Transluminal Angioplasty (PTA) Balloons-Medical Devices Pipeline Assessment, 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Percutaneous Transluminal Angioplasty (PTA) Balloons-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Percutaneous Transluminal Angioplasty (PTA) Balloons-Medical Devices Pipeline Assessment, 2017" provides an overview of Percutaneous Transluminal Angioplasty (PTA) Balloons currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Balloons pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Balloons under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Balloons and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to Buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Balloons under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Percutaneous Transluminal Angioplasty (PTA) Balloons Overview 7

3 Products under Development 8

3.1 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

3.2 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

3.3 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

3.4 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

3.5 Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12

4 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products under Development by Companies 13

4.1 Percutaneous Transluminal Angioplasty (PTA) Balloons Companies-Pipeline Products by Stage of Development 13

4.2 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 14

5 Percutaneous Transluminal Angioplasty (PTA) Balloons Companies and Product Overview 15

5.1 Andramed GmbH Company Overview 15

5.1.1 Andramed GmbH Pipeline Products & Ongoing Clinical Trials Overview 15

5.2 Boston Scientific Corp Company Overview 16

5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

5.3 C. R. Bard Inc Company Overview 17

5.3.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Cagent Vascular LLC Company Overview 21

5.4.1 Cagent Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Contego Medical, LLC Company Overview 22

5.5.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Hexacath SA Company Overview 26

5.6.1 Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview 26

5.7 MicroPort Scientific Corp Company Overview 27

5.7.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 27

5.8 NuVascular Technologies Inc Company Overview 29

5.8.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29

5.9 Occlutech International AB Company Overview 30

5.9.1 Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview 30

5.10 QT Vascular Ltd Company Overview 31

5.10.1 QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.11 SurModics Inc Company Overview 34

5.11.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

6 Percutaneous Transluminal Angioplasty (PTA) Balloons- Recent Developments 38

6.1 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 38

6.2 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 38

6.3 Feb 27, 2017: AV Medical's Chameleon Receives Expanded Indication to Include Infusion of Diagnostic or Therapeutic Fluids 39

6.4 Feb 23, 2017: Teleflex Announces Benson Smith to Retire as Chief Executive Officer at End of 2017; Liam Kelly to Succeed Smith as Chief Executive Officer 40

6.5 Feb 23, 2017: Teleflex Reports Fourth Quarter and Full Year 2016 Results; Provides 2017 Guidance 40

6.6 Feb 23, 2017: Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million 42

6.7 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 43

6.8 Feb 09, 2017: Terumo Announces Change of Executive Officers 45

6.9 Feb 08, 2017: AV Medical's Chameleon PTA Balloon Catheter to be Featured at Upcoming ASDIN Scientific Meeting 46

6.10 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 47

6.11 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 47

6.12 Feb 02, 2017: Surmodics Reports First Quarter Fiscal 2017 Results 49

6.13 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 50

6.14 Jan 31, 2017: Terumo Opens a Branch in Yangon 52

6.15 Jan 26, 2017: Bard Announces Fourth Quarter Results 52

6.16 Jan 19, 2017: Terumo to Acquire Bolton Medical from Werfen Life 53

6.17 Jan 12, 2017: STENTYS: 2016 Annual Revenues up 20% at 7.3 Million 53

6.18 Jan 11, 2017: Spectranetics Names Scott Hutton as General Manager, Vascular Intervention 54

6.19 Dec 19, 2016: MicroPort Endovascular Received CE Mark Approval for Reewarm Peripheral Balloon Dilation Catheter 54

6.20 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 55

6.21 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 55

6.22 Dec 01, 2016: Teleflex Acquires Vascular Solutions for up to USD1 Billion 57

6.23 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 58

6.24 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 61

6.25 Nov 16, 2016: Surmodics Reports Fourth Quarter Fiscal 2016 Results 61

6.26 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 63

6.27 Oct 31, 2016: Surmodics Announces Launch of Serene Single-Coat (SC) Solutions Offering Unmatched Lubricity and Durability to a Broader Range of Device Applications 63

6.28 Oct 27, 2016: Svelte Medical receives CE Mark for new treatment of coronary artery disease 64

6.29 Oct 27, 2016: Teleflex Reports Third Quarter 2016 Results 64

6.30 Oct 27, 2016: Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million 67

6.31 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 67

6.32 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 69

6.33 Oct 25, 2016: Bard Announces Third Quarter Results 71

6.34 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results 71

6.35 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 74

6.36 Sep 22, 2016: LUTONIX Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016 75

6.37 Sep 21, 2016: AV Medical's Chameleon PTA Balloon Catheter Featured in Radiation Protection Pavilion at CIRSE Conference 75

6.38 Sep 15, 2016: STENTYS Reports 2016 First-Half Results 76

6.39 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 77

6.40 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 78

6.41 Aug 30, 2016: MPSC Announces 2016 Interim Results 79

6.42 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 80

6.43 Jul 28, 2016: Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million 83

6.44 Jul 28, 2016: Surmodics Reports Third Quarter Fiscal 2016 Results 84

6.45 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 85

6.46 Jul 28, 2016: Teleflex Reports Second Quarter 2016 Results 87

6.47 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results 88

6.48 Jul 26, 2016: Bard Announces Second Quarter Results 90

6.49 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment 91

6.50 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment 91

6.51 Jul 25, 2016: Vascular Solutions Reports Second Quarter Results 92

6.52 Jul 21, 2016: Federal Circuit Court Rules in Appeal 94

6.53 Jul 20, 2016: Contego Medical Completes Enrollment of Paladin Clinical Registry 95

6.54 Jul 18, 2016: AV Medical Announces Initial Experience in the US with Its Chameleon PTA Balloon Catheter 95

6.55 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 96

6.56 Jul 12, 2016: STENTYS: 41% Increase in Revenues in the Second Quarter of 2016 96

6.57 Jul 04, 2016: STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO 97

6.58 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 97

6.59 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 98

6.60 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 98

6.61 Jun 03, 2016: LEPUCARE established in India 99

6.62 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 99

6.63 May 24, 2016: OrbusNeich Introduces News JADE catheter to Treat Peripheral Disease 102

6.64 May 24, 2016: OrbusNeich Expands Portfolio To Include Scoreflex PTA balloon Catheter 103

6.65 May 11, 2016: Teleflex Raises USD400 Million in Public Offering of 4.875% Notes Due 2026 103

6.66 Apr 21, 2016: AV Medical Announces Successful Completion of 30 Patient Study with its Innovative Angioplasty Balloon Catheter, Chameleon 104

6.67 Apr 13, 2016: STENTYS Reports 38% Increase in Revenues in First Quarter 2016 104

6.68 Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device 104

7 Appendix 106

7.1 Methodology 106

7.2 About GlobalData 109

7.3 Contact Us 109

7.4 Disclaimer 109


List Of Figure

1.2 List of Figures

Figure 1: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

Figure 2: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

Figure 3: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

Figure 4: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

Figure 5: Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12


List Of Table

1.1 List of Tables

Table 1: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

Table 2: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

Table 3: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

Table 4: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

Table 5: Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12

Table 6: Percutaneous Transluminal Angioplasty (PTA) Balloons Companies-Pipeline Products by Stage of Development 13

Table 7: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 14

Table 8: Andramed GmbH Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Zero-Profile PTA Balloon-Product Status 15

Table 10: Zero-Profile PTA Balloon-Product Description 15

Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Next Generation 0.018" Balloon-Product Status 16

Table 13: Next Generation 0.018" Balloon-Product Description 16

Table 14: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-Product Status 17

Table 16: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-Product Description 18

Table 17: Ultrascore-Product Status 18

Table 18: Ultrascore-Product Description 18

Table 19: C. R. Bard Inc-Ongoing Clinical Trials Overview 19

Table 20: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions 20

Table 21: Cagent Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview 21

Table 22: Serranator Bass-Product Status 21

Table 23: Serranator Bass-Product Description 21

Table 24: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 25: PALADIN-Product Status 22

Table 26: PALADIN-Product Description 22

Table 27: Superficial Femoral Artery Balloon-Product Status 23

Table 28: Superficial Femoral Artery Balloon-Product Description 23

Table 29: Contego Medical, LLC-Ongoing Clinical Trials Overview 24

Table 30: PALADIN-Multi-center Study to Evaluate Acute Safety and Clinical Performance of Paladin Carotid Post-dilation Balloon with Integrated Embolic Protection 25

Table 31: Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview 26

Table 32: MERAK PTA Dilatation Catheter-Product Status 26

Table 33: MERAK PTA Dilatation Catheter-Product Description 26

Table 34: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 27

Table 35: Reewarm14-Product Status 27

Table 36: Reewarm14-Product Description 27

Table 37: Reewarm18 Peripheral Balloon Dilation Catheter-Product Status 28

Table 38: Reewarm18 Peripheral Balloon Dilation Catheter-Product Description 28

Table 39: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 40: NuSpun DE Balloon-Product Status 29

Table 41: NuSpun DE Balloon-Product Description 29

Table 42: Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview 30

Table 43: Occlutech Sizing Balloon-Product Status 30

Table 44: Occlutech Sizing Balloon-Product Description 30

Table 45: QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

Table 46: Chocolate PTA Balloon Catheter-Product Status 31

Table 47: Chocolate PTA Balloon Catheter-Product Description 31

Table 48: QT Vascular Ltd-Ongoing Clinical Trials Overview 32

Table 49: Chocolate PTA Balloon Catheter-Procedural Success Assessment After Treatment With Drug Coated Chocolate Balloon 33

Table 50: SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Table 51: 0.018" OTW Dual Lumen PTA Catheter-Product Status 34

Table 52: 0.018" OTW Dual Lumen PTA Catheter-Product Description 35

Table 53: 0.018" RX Dual Lumen PTA Catheter-Product Status 35

Table 54: 0.018" RX Dual Lumen PTA Catheter-Product Description 35

Table 55: 0.035" Large Diameter OTW PTA Catheter-Product Status 36

Table 56: 0.035" Large Diameter OTW PTA Catheter-Product Description 36

Table 57: 0.035" Next Generation Workhorse PTA Catheter-Product Status 36

Table 58: 0.035" Next Generation Workhorse PTA Catheter-Product Description 37

Table 59: Glossary 108

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Andramed GmbH, Boston Scientific Corp, C. R. Bard Inc, Cagent Vascular LLC, Contego Medical, LLC, Hexacath SA, MicroPort Scientific Corp, NuVascular Technologies Inc, Occlutech International AB, QT Vascular Ltd, SurModics Inc

Percutaneous Transluminal Angioplasty (PTA) Balloons-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Percutaneous Transluminal Angioplasty (PTA) Balloons-Medical Devices Pipeline Assessment, 2017" provides an overview of Percutaneous Transluminal Angioplasty (PTA) Balloons currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Balloons pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Balloons under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Balloons and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to Buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Balloons under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Percutaneous Transluminal Angioplasty (PTA) Balloons Overview 7

3 Products under Development 8

3.1 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

3.2 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

3.3 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

3.4 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

3.5 Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12

4 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products under Development by Companies 13

4.1 Percutaneous Transluminal Angioplasty (PTA) Balloons Companies-Pipeline Products by Stage of Development 13

4.2 Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 14

5 Percutaneous Transluminal Angioplasty (PTA) Balloons Companies and Product Overview 15

5.1 Andramed GmbH Company Overview 15

5.1.1 Andramed GmbH Pipeline Products & Ongoing Clinical Trials Overview 15

5.2 Boston Scientific Corp Company Overview 16

5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

5.3 C. R. Bard Inc Company Overview 17

5.3.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Cagent Vascular LLC Company Overview 21

5.4.1 Cagent Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Contego Medical, LLC Company Overview 22

5.5.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Hexacath SA Company Overview 26

5.6.1 Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview 26

5.7 MicroPort Scientific Corp Company Overview 27

5.7.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 27

5.8 NuVascular Technologies Inc Company Overview 29

5.8.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29

5.9 Occlutech International AB Company Overview 30

5.9.1 Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview 30

5.10 QT Vascular Ltd Company Overview 31

5.10.1 QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.11 SurModics Inc Company Overview 34

5.11.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

6 Percutaneous Transluminal Angioplasty (PTA) Balloons- Recent Developments 38

6.1 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 38

6.2 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 38

6.3 Feb 27, 2017: AV Medical's Chameleon Receives Expanded Indication to Include Infusion of Diagnostic or Therapeutic Fluids 39

6.4 Feb 23, 2017: Teleflex Announces Benson Smith to Retire as Chief Executive Officer at End of 2017; Liam Kelly to Succeed Smith as Chief Executive Officer 40

6.5 Feb 23, 2017: Teleflex Reports Fourth Quarter and Full Year 2016 Results; Provides 2017 Guidance 40

6.6 Feb 23, 2017: Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million 42

6.7 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 43

6.8 Feb 09, 2017: Terumo Announces Change of Executive Officers 45

6.9 Feb 08, 2017: AV Medical's Chameleon PTA Balloon Catheter to be Featured at Upcoming ASDIN Scientific Meeting 46

6.10 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 47

6.11 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 47

6.12 Feb 02, 2017: Surmodics Reports First Quarter Fiscal 2017 Results 49

6.13 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 50

6.14 Jan 31, 2017: Terumo Opens a Branch in Yangon 52

6.15 Jan 26, 2017: Bard Announces Fourth Quarter Results 52

6.16 Jan 19, 2017: Terumo to Acquire Bolton Medical from Werfen Life 53

6.17 Jan 12, 2017: STENTYS: 2016 Annual Revenues up 20% at 7.3 Million 53

6.18 Jan 11, 2017: Spectranetics Names Scott Hutton as General Manager, Vascular Intervention 54

6.19 Dec 19, 2016: MicroPort Endovascular Received CE Mark Approval for Reewarm Peripheral Balloon Dilation Catheter 54

6.20 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 55

6.21 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 55

6.22 Dec 01, 2016: Teleflex Acquires Vascular Solutions for up to USD1 Billion 57

6.23 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 58

6.24 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 61

6.25 Nov 16, 2016: Surmodics Reports Fourth Quarter Fiscal 2016 Results 61

6.26 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 63

6.27 Oct 31, 2016: Surmodics Announces Launch of Serene Single-Coat (SC) Solutions Offering Unmatched Lubricity and Durability to a Broader Range of Device Applications 63

6.28 Oct 27, 2016: Svelte Medical receives CE Mark for new treatment of coronary artery disease 64

6.29 Oct 27, 2016: Teleflex Reports Third Quarter 2016 Results 64

6.30 Oct 27, 2016: Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million 67

6.31 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 67

6.32 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 69

6.33 Oct 25, 2016: Bard Announces Third Quarter Results 71

6.34 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results 71

6.35 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 74

6.36 Sep 22, 2016: LUTONIX Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016 75

6.37 Sep 21, 2016: AV Medical's Chameleon PTA Balloon Catheter Featured in Radiation Protection Pavilion at CIRSE Conference 75

6.38 Sep 15, 2016: STENTYS Reports 2016 First-Half Results 76

6.39 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 77

6.40 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 78

6.41 Aug 30, 2016: MPSC Announces 2016 Interim Results 79

6.42 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 80

6.43 Jul 28, 2016: Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million 83

6.44 Jul 28, 2016: Surmodics Reports Third Quarter Fiscal 2016 Results 84

6.45 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 85

6.46 Jul 28, 2016: Teleflex Reports Second Quarter 2016 Results 87

6.47 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results 88

6.48 Jul 26, 2016: Bard Announces Second Quarter Results 90

6.49 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment 91

6.50 Jul 25, 2016: QT Vascular Announces Federal Circuit Reversal of Adverse AngioScore / Spectranetics Judgment 91

6.51 Jul 25, 2016: Vascular Solutions Reports Second Quarter Results 92

6.52 Jul 21, 2016: Federal Circuit Court Rules in Appeal 94

6.53 Jul 20, 2016: Contego Medical Completes Enrollment of Paladin Clinical Registry 95

6.54 Jul 18, 2016: AV Medical Announces Initial Experience in the US with Its Chameleon PTA Balloon Catheter 95

6.55 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 96

6.56 Jul 12, 2016: STENTYS: 41% Increase in Revenues in the Second Quarter of 2016 96

6.57 Jul 04, 2016: STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO 97

6.58 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 97

6.59 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 98

6.60 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 98

6.61 Jun 03, 2016: LEPUCARE established in India 99

6.62 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 99

6.63 May 24, 2016: OrbusNeich Introduces News JADE catheter to Treat Peripheral Disease 102

6.64 May 24, 2016: OrbusNeich Expands Portfolio To Include Scoreflex PTA balloon Catheter 103

6.65 May 11, 2016: Teleflex Raises USD400 Million in Public Offering of 4.875% Notes Due 2026 103

6.66 Apr 21, 2016: AV Medical Announces Successful Completion of 30 Patient Study with its Innovative Angioplasty Balloon Catheter, Chameleon 104

6.67 Apr 13, 2016: STENTYS Reports 38% Increase in Revenues in First Quarter 2016 104

6.68 Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device 104

7 Appendix 106

7.1 Methodology 106

7.2 About GlobalData 109

7.3 Contact Us 109

7.4 Disclaimer 109


List Of Figure

1.2 List of Figures

Figure 1: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

Figure 2: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

Figure 3: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

Figure 4: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

Figure 5: Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12


List Of Table

1.1 List of Tables

Table 1: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 8

Table 2: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Territory 9

Table 3: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Regulatory Path 10

Table 4: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Estimated Approval Date 11

Table 5: Percutaneous Transluminal Angioplasty (PTA) Balloons-Ongoing Clinical Trials 12

Table 6: Percutaneous Transluminal Angioplasty (PTA) Balloons Companies-Pipeline Products by Stage of Development 13

Table 7: Percutaneous Transluminal Angioplasty (PTA) Balloons-Pipeline Products by Stage of Development 14

Table 8: Andramed GmbH Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Zero-Profile PTA Balloon-Product Status 15

Table 10: Zero-Profile PTA Balloon-Product Description 15

Table 11: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Next Generation 0.018" Balloon-Product Status 16

Table 13: Next Generation 0.018" Balloon-Product Description 16

Table 14: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-Product Status 17

Table 16: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-Product Description 18

Table 17: Ultrascore-Product Status 18

Table 18: Ultrascore-Product Description 18

Table 19: C. R. Bard Inc-Ongoing Clinical Trials Overview 19

Table 20: LUTONIX 035 Drug Coated Balloon PTA Catheter-Long Femoropopliteal Lesions-A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions 20

Table 21: Cagent Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview 21

Table 22: Serranator Bass-Product Status 21

Table 23: Serranator Bass-Product Description 21

Table 24: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22

Table 25: PALADIN-Product Status 22

Table 26: PALADIN-Product Description 22

Table 27: Superficial Femoral Artery Balloon-Product Status 23

Table 28: Superficial Femoral Artery Balloon-Product Description 23

Table 29: Contego Medical, LLC-Ongoing Clinical Trials Overview 24

Table 30: PALADIN-Multi-center Study to Evaluate Acute Safety and Clinical Performance of Paladin Carotid Post-dilation Balloon with Integrated Embolic Protection 25

Table 31: Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview 26

Table 32: MERAK PTA Dilatation Catheter-Product Status 26

Table 33: MERAK PTA Dilatation Catheter-Product Description 26

Table 34: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 27

Table 35: Reewarm14-Product Status 27

Table 36: Reewarm14-Product Description 27

Table 37: Reewarm18 Peripheral Balloon Dilation Catheter-Product Status 28

Table 38: Reewarm18 Peripheral Balloon Dilation Catheter-Product Description 28

Table 39: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29

Table 40: NuSpun DE Balloon-Product Status 29

Table 41: NuSpun DE Balloon-Product Description 29

Table 42: Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview 30

Table 43: Occlutech Sizing Balloon-Product Status 30

Table 44: Occlutech Sizing Balloon-Product Description 30

Table 45: QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

Table 46: Chocolate PTA Balloon Catheter-Product Status 31

Table 47: Chocolate PTA Balloon Catheter-Product Description 31

Table 48: QT Vascular Ltd-Ongoing Clinical Trials Overview 32

Table 49: Chocolate PTA Balloon Catheter-Procedural Success Assessment After Treatment With Drug Coated Chocolate Balloon 33

Table 50: SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Table 51: 0.018" OTW Dual Lumen PTA Catheter-Product Status 34

Table 52: 0.018" OTW Dual Lumen PTA Catheter-Product Description 35

Table 53: 0.018" RX Dual Lumen PTA Catheter-Product Status 35

Table 54: 0.018" RX Dual Lumen PTA Catheter-Product Description 35

Table 55: 0.035" Large Diameter OTW PTA Catheter-Product Status 36

Table 56: 0.035" Large Diameter OTW PTA Catheter-Product Description 36

Table 57: 0.035" Next Generation Workhorse PTA Catheter-Product Status 36

Table 58: 0.035" Next Generation Workhorse PTA Catheter-Product Description 37

Table 59: Glossary 108

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Andramed GmbH, Boston Scientific Corp, C. R. Bard Inc, Cagent Vascular LLC, Contego Medical, LLC, Hexacath SA, MicroPort Scientific Corp, NuVascular Technologies Inc, Occlutech International AB, QT Vascular Ltd, SurModics Inc